Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Biotech’s Fortunes Riding On Other Assets
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.